RTP-026

Product Description

RTP-026 activates tissue reparative pathways by targeting innate immune cells. Our preclinical data shows that RTP-026 works by: Regulating neutrophil and monocyte recruitment to injured tissue, Promoting neutrophil apoptosis and thereby limiting destruction of, surrounding tissue, Removing apoptotic cells through efferocytosis, Promoting macrophage switch towards a pro-resolving phenotype. Together, these orchestrated cellular events contribute to resolution of inflammation and activation of cellular event that support tissue healing. RTP-026 mimics the action of Annexin A1 and initiates resolution and tissue repair through its action on a G-protein coupled receptor expressed on the surface of leukocytes. (Sourced from: https://resotherpharma.com/research/#:~:text=RTP%2D026%20activates%20tissue%20reparative,limiting%20destruction%20of%20surrounding%20tissue)

Mechanisms of Action: FPR2 Modulator

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ResoTher Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None